The HAMP domain is present in a large number of transmembrane proteins in prokaryotes including histidine kinases, adenylyl cyclases, chemotaxis receptors, and phosphatases. In this issue of Cell, Hulko et al. (2006) report the NMR structure of a HAMP domain and present data suggesting that it transduces signals through a simple rotation of its four-helix parallel coiled coil.
Much of our understanding of biology at the molecular level has emerged because of the development of strategies to perturb the function of proteins, including genetic approaches, RNA interference (RNAi), and the use of small molecules. With genetics, the timescale of the perturbation depends on the development of the organism (or with RNAi on the halflife of the protein). In contrast, inhibition by small molecules is rapid (with timescales of seconds to minutes) and often reversible, as binding is often not covalent. The use of smallmolecule inhibitors has a rich history. Classic examples include the use of colchicine and Brefeldin A to examine cell division and membrane trafficking, respectively (reviewed in Inoue and Sato, 1967; Jackson, 2000) . However, the strength of genetics is that it can be applied to any protein with superb specificity because any gene can be targeted for mutation or deletion without directly affecting any other gene. In contrast, the use of small molecules is limited to those proteins for which inhibitors have been identified, and discovery of new inhibitors is challenging. Also, it is difficult to demonstrate that a small molecule is specific for a single target, and specificity often depends on the concentration of the inhibitor that is used.
An ideal strategy would combine the specificity of genetics with the temporal control and reversibility of small molecules. Progress toward this goal has been made by designing mutations or genetically encoded tags that make the target protein, but not endogenous unmodified proteins, susceptible to a small molecule (reviewed in Shogren-Knaak et al., 2001) . In this issue of Cell, add to the arsenal of approaches that follow this general design. They describe a strategy in which a small molecule is used to control the degradation of a genetically tagged target protein.
Several strategies to control protein degradation with small molecules have been described previously (reviewed in . One attractive approach has been to exploit the FKBP-rapamycin-FRB complex (see Table 1 for nomenclature). Rapamycin is a small molecule that binds to the immunophilin FKBP12; the rapamycin-FKBP12 complex then binds to the FRB domain of FRAP/ mTOR. In one approach implemented in yeast, FKBP was fused to a subunit of the proteasome and FRB was used to tag a target protein (Janse et al., 2004) . Upon addition of rapamycin, the target protein was successfully localized to the proteasome and degraded. In a second approach, a fusion protein comprising FKBP and green fluorescent protein (GFP) was targeted for proteasomal degradation by treatment with a bifunctional small molecule containing both an FKBP ligand and a ligand for an E3 ubiquitin ligase (Schneekloth et al., 2004) . In a third approach, which served as the starting point for the current study, a target protein, the kinase GSK-3β, was fused to the FRB domain (Stankunas et al., 2003 MaRAP C20-methallylrapamycin, synthetic rapamycin derivative that binds FRB* but not wt-FRB.
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Shield-1, FKBP ligand that binds FKBP with F36V mutation with 1000 selectivity over wt-FKBP.
domains, a mutated FRB domain (FRB*) was used with a rapamycin analog (MaRAP) that binds to FRB* but not wild-type FRB. The surprising finding was that GSK-3β-FRB* was degraded when expressed in mouse fibroblasts, whereas GSK-3β-FRB or unmodified GSK-3β remained stable. Furthermore, treatment with rapamycin or MaRAP stabilized the GSK-3β-FRB* fusion protein. A knockin mouse was constructed with GSK-3β-FRB* to demonstrate that levels of GSK-3β could be controlled in vivo using a small molecule. Banaszynski and colleagues set out to address some shortcomings in the strategy that uses MaRAP-FRB* for the inducible stabilization of a target protein. First, as MaRAP binds to FKBP12 in order to bind FRB, two protein domains are required for stabilization. Second, MaRAP is not ideal as a ligand, as it is expensive and has poor pharmacokinetic properties that are likely related to its short half-life in serum (Stankunas et al., 2003) . The goal of the current study was to identify an alternative ligand-dependent destabilizing domain. FKBP12 was selected as a candidate, in part because a wide variety of synthetic ligands are available. In particular, a ligand had been developed that binds to a mutated FKBP12 (bearing a F36V mutation) with 1000-fold selectivity over wildtype FKBP12 (Clackson et al., 1998) . A modified version of this ligand with improved pharmacokinetic properties, called Shield-1 (Shld1), was used in the current study.
To identify mutations in FKBP that might make it stable in the presence but not the absence of ligand, an FKBP library was generated by error-prone PCR and used to tag yellow fluorescent protein (YFP). This library was expressed in mouse fibroblast cells, and the cells were sorted by flow cytometry. After several rounds of sorting, a population of cells was isolated that exhibited YFP fluorescence in the presence but not the absence of ligand, suggesting that the ligand prevented destabilization of the tagged YFP. For the mutation in FKBP that was the most destabilizing (L106P), YFP was degraded almost completely within 4 hr after removal of the ligand. To demonstrate that this may be a general approach to affect protein stability, several different proteins were tagged with the destabilizing domain. Examples include several classes of proteins, such as kinases, small GTPases, and a transmembrane glycoprotein. Ligand-dependent stabilization was observed in all cases. Constitutively active mutants of several small GTPases (RhoA, Cdc42, and Arl7) tagged with the destabilizing domain were used to show that cellular phenoyptes could be controlled by adding or removing the ligand. In each case the expected morphological change associated with expression of the active mutant was observed in the presence of ligand. The phenotypes were reversed after removal of ligand.
There are some limitations to this approach. Although levels of a tagged protein may be controlled, the endogenous protein is unaffected. In genetic systems, a knockin strategy would circumvent this problem, as was demonstrated for the destabilizing FRB* domain (Stankunas et al., 2003) . Alternatively, dominantnegative or constitutively active constructs can be used to introduce perturbations that do not depend on removing the endogenous protein. Ironically, this strategy is reminiscent of those used before the advent of RNAi when such methods were often the only ones available for systems not amenable to genetic approaches, such as cultured cell lines. Of course, the advantage of expressing these constructs with the destabilizing domain is that the perturbation can be introduced with a higher degree of temporal control and is reversible. The temporal control depends either on protein synthesis or on degradation of the tagged protein by the proteasome, depending on whether the ligand is added or removed. As the efficiency of both processes likely varies across the cell cycle, the effectiveness of the technique may depend on cell-cycle state.
The approach described by Banaszynski and colleagues offers a promising compromise between the use of genetics and small molecules. It should allow perturbations of protein function on timescales considerably shorter than either genetics or RNAi, though not as rapid as direct small-molecule inhibition (Figure 1) . The FKBP tag can in principle be added to any protein, which makes the technique more generally applicable than smallmolecule inhibition. However, not all proteins may be easily tagged and the endogenous protein must be accounted for. The combination of temporal control on a timescale of hours with the specificity of a simple genetically encoded tag should provide a valuable addition to the continually expanding toolbox for chemical biology. A future goal may be to employ a similar strategy with a tag that can be removed in a chemically controlled way, leaving the protein in a wild-type state.
Figure 1. Timescales of Biological Processes and Experimental Perturbations
The use of perturbations that act on a relevant timescale facilitates the design of experiments to probe complex biological systems.
